Severe COVID-19 pneumonia in an intensive care setting and comparisons with historic severe viral pneumonia due to other viruses

Kiran Dadhwal  
University Hospital Southampton NHS Foundation Trust

Rosalind Stonham  
Southampton University Hospitals NHS Trust: University Hospital Southampton NHS Foundation Trust

Stephen Poole  
University of Southampton

Kordo Saeed (kordosaeed@nhs.net)  
University Hospital Southampton NHS Foundation Trust  
https://orcid.org/0000-0003-0123-0302

Ahilanandan Dushianthan  
Southampton University Hospitals NHS Trust: University Hospital Southampton NHS Foundation Trust

Research Article

Keywords: COVID-19, Viral Pneumonia, Intensive Care

DOI: https://doi.org/10.21203/rs.3.rs-583767/v1

License: ©️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Purpose

Severe viral pneumonia is associated with significant morbidity and mortality. Recent COVID-19 pandemic continues to impose significant health burden worldwide and individual pandemic waves often leads to a large surge in the ICU admissions for respiratory support. Comparisons of severe SARS-CoV-2 pneumonia with other seasonal and non-seasonal severe viral infections are rarely studied in an intensive care setting.

Methods

A retrospective cohort study comparing patients admitted to ICU with COVID-19 between March-June 2020 and those with viral pneumonias between January-December 2019. We compared patient specific demographic variables, duration of illness, ICU organ supportive measures and outcomes between both groups.

Results

Analysis of 93 COVID-19 (group 1) and 52 other viral pneumonia patients (group 2) showed an increased proportion of obesity (42% vs 23%, \( p = 0.02 \)), non-white ethnicities (41% vs 6%, \( p < 0.001 \)) and diabetes mellitus (30% vs 13%, \( p = 0.03 \)) in group 1, with lower prevalence of COPD/asthma (16% vs 34%, \( p = 0.02 \)). In group 1, the neutrophil to lymphocyte ratio was much lower (6.7 vs 10, \( p = 0.006 \)) and invasive mechanical ventilation (58% vs 26%, \( p < 0.001 \)) was more common. Length of ICU (8 vs 4, \( p < 0.001 \)) and hospital stay (22 vs 11, \( p < 0.001 \)) was prolonged in group 1, with no significant difference in mortality. Influenza A and rhinovirus were the most common pathogens in group 2 (26% each).

Conclusions

Key differences were identified within demographics (obesity, ethnicity, age, ICU scores, co-morbidities) and organ support. Despite these variations, there was no significant differences in mortality between both groups. Further studies with larger sample sizes would allow for further assessment of clinical parameters in these patients.

Introduction

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was first identified as a novel human pathogen following reports of pneumonia of unknown aetiology in Wuhan, China, in December 2019. The evolving pandemic has caused > 3 million reported deaths worldwide so far and imposes a significant
burden on critical care services, necessitating vast critical care expansion in the UK, equivalent to 141 new intensive care units (ICUs) over the past 12 months [1].

Critical illness of COVID-19 pneumonia is associated with acute hypoxic respiratory failure (AHRF) and for mechanically ventilated patients, the mortality remains high [2]. The severity of illness is associated with a selective susceptibility of patients with advanced age and cardiovascular and metabolic comorbidities [3]. Viral pneumonia in general is relatively common and is an important cause of severe respiratory infections in an ICU setting. Reported incidence of severe viral pneumonia varies seasonally worldwide and the common viruses that cause severe respiratory failure include influenza viruses, respiratory syncytial virus (RSV) and rhinovirus causing significant mortality and morbidity across all age groups [4]. Although there are several studies from various clinical settings comparing the demographic data, laboratory findings and clinical outcomes of COVID-19 pneumonia with influenza, there remains lack of comparative studies in the critical care setting. The purpose of this study is therefore to compare the patient specific variables, organ supportive measures and outcomes of patients admitted with COVID-19 pneumonia with other causes of viral pneumonia of critically ill patients in the intensive care setting.

Methods

Study design and participants

We performed a cohort study of adults (> 18 years) admitted to the ICU at University Hospital Southampton, UK who tested positive for respiratory viruses between January 2019 and X. Southampton General is a large tertiary referral centre on the South coast of England, offering secondary care services to a population of around 650,000 people.

SARS-CoV-2 positive patients were identified retrospectively from laboratory RT-PCR results between 03/03/2020 and 08/06/2020 who had results corresponding to an ICU admission. Testing was performed on-site, initially using the Public Health England (PHE) RpRp-gene assay, and later using the PHE RdRp-gene and E-gene combined assay. Respiratory virus testing at this time was restricted to SARS-CoV-2 alone due to limited availability of reagent during the first peak of the pandemic.

The comparator group were identified in the same way, with a positive laboratory PCR result between 1 January 2019 and 31 December 2019. The laboratory assay tested for adenovirus, influenza A, influenza B, human metapneumovirus (hMPV), parainfluenza viruses (PIV) (type 1, 2 and 3), human rhinovirus (hRV) and RSV. The study was approved by local ethics committee for retrospective data collection (RHM CRI 0370/ IRAS 232922) and due to the nature of the study patient consent was waived. This study is reported according to the STROBE guideline [5].

Data collection

Anonymised data was collected from existing electronic hospital patient records. All relevant clinical details were collected including baseline patient demographics, comorbidities (described using Charlson's
comorbidity index [6]), Acute Physiology and Chronic Health Evaluation II score (APACHE II), The Sequential Organ Failure Assessment Score (SOFA), oxygenation index (PaO$_2$/FiO$_2$), admission laboratory variables, and events during GICU admission including use of non-invasive ventilation, the need for mechanical ventilation and haemofiltration. The outcomes reported are duration of ICU length of stay, total hospitalised days, 28-day mortality, ICU mortality and hospital mortality. APACHE II variables were collected at the first 24 hours of ICU admission. The oxygenation index represents lowest PaO$_2$/FiO$_2$ on admission to ICU. Severe community acquired pneumonia is defined in accordance to published American Thoracic Society/Infectious Diseases Society of America guidelines [7].

**Statistical analysis**

Baselines characteristics of all positive viral detections were summarised using appropriate descriptive statistics. Continuous data are presented as medians and interquartile ranges, and categorical data as numbers and percentages. Absolute differences between proportions are presented with 95% confidence intervals. Differences and 95% confidence intervals between medians were calculated using the Hodges-Lehmann estimator. Comparative statistical tests were performed between SARS-CoV-2 and non-SARS-CoV-2 viral positive cases. For descriptive statistics, data are presented as median with interquartile ranges as variables were found to be non-normal distribution assessed by the Kolmogorov-Smirnov test. Comparison of proportions was performed using two-sided Fisher's exact test. Data analysis was performed using GraphPad Prism 8.4 (GraphPad Software, LLC).

**Results**

There were 93 COVID-19 patients admitted to the intensive care unit during March 2020- June 2020 for respiratory support and 52 non-SARS-CoV-2 viral pneumonia patients admitted in the year 2019 who met the criteria for the inclusion in the study. We classified the COVID-19 pneumonia patients as group one and the historical cohort as group 2. The demographics for both groups are presented in Table 1. The median age for the COVID-19 group was much lower at 57 (IQR 47,65). Moreover, although there was an increased male predominance for COVID-19, this was not statistically significant. The median onset of symptoms was shorter for non-COVID-19 viral pneumonia. There was an increased proportion of obesity with BMI > 30kg/m$^2$ in the COVID-19 group accounting for 43% in comparison to less than quarter in group 2. There was an increased ethnicity prevalence in COVID-19 group and 37% of all admissions were non-white Caucasian (Table 1).
Table 1

Patient demographics on admission, disease severity indices, intensive care interventions and admission laboratory markers from all COVID-19 admitted patients. Data are presented as median (Interquartile Range) or numbers (percentage) unless otherwise stated. *P < 0.05 as assessed by Fisher’s Exact test for categorical variables and Mann-Whitney U test for continuous variables. APACHE II, Acute Physiology and Chronic Health Evaluation II score; BMI, Body Mass Index; PaO$_2$/FiO$_2$, ratio of arterial oxygen partial pressure to fractional inspired oxygen; SOFA, Sequential Organ Failure Assessment score.

| Variables                              | Group 1                                      | Group 2                                      | p-value |
|----------------------------------------|----------------------------------------------|----------------------------------------------|---------|
| **COVID 19 pneumonia (N = 93)**        |                                              |                                              |         |
| Age                                    | 58 (47, 66)                                  | 65 (50, 71)                                  | 0.13    |
| Male (%)                               | 60%                                          | 45%                                          | 0.09    |
| Symptomatic days prior to admission    | 7 (5, 10)                                    | 4 (3, 7)                                     | < 0.001*|
| BMI > 30 kg/m$^2$, n (%)               | 39 (41.9%)                                   | 12 (22.6%)                                   | 0.02*   |
| Clinical Frailty Scale (CFS)           | 2 (1, 3)                                     | 3 (3, 5)                                     | < 0.001*|
| Charlson’s comorbidity index (CCI)     | 2 (1, 3)                                     | 3 (1.5, 5)                                   | 0.02*   |
| Race/ethnic group                      |                                              |                                              |         |
| White, n (%)                           | 55 (59%)                                     | 50 (94%)                                     | < 0.001*|
| Other, n (%)                           | 38 (41%)                                     | 3 (6%)                                       |         |
| **Comorbidities, n (%)**               |                                              |                                              |         |
| COPD/Asthma                            | 15 (16.1%)                                   | 18 (34.0%)                                   | 0.02*   |
| Other respiratory disease              | 7 (7.5%)                                     | 7 (13.2%)                                    | 0.38    |
| Chronic kidney disease                 | 7 (7.5%)                                     | 7 (13.2%)                                    | 0.38    |
| Congestive cardiac failure             | 4 (4.3%)                                     | 3 (5.7%)                                     | 0.70    |
| Diabetes mellitus                      | 28 (30.0%)                                   | 7 (13.2%)                                    | 0.03*   |
| Hypertension                           | 38 (40.9%)                                   | 14 (26.4%)                                   | 0.11    |
| Ischemic heart disease                 | 8 (8.6%)                                     | 5 (9.4%)                                     | 0.99    |
| Immunosuppression                      | 13 (14.0%)                                   | 13 (24.5%)                                   | 0.12    |
| **ICU severity indices**               |                                              |                                              |         |
| APACHE II Score                        | 14 (11, 23)                                  | 14 (9.5, 19)                                 | 0.18    |
| SOFA Score                             | 4 (3, 6)                                     | 3 (2, 6)                                     | 0.09    |
### Variables

| Variables                        | Group 1                  | Group 2                  | p-value |
|----------------------------------|--------------------------|--------------------------|---------|
| **COVID 19 pneumonia (N = 93)**  |                          |                          |         |
| PaO$_2$/FiO$_2$ ratio (mmHg)     | 114.8 (99.0, 137.3)      | 126.8 (95.3, 203.3)      | 0.11    |
| **Other Viral pneumonia (N = 53)** |                          |                          |         |
| Admission laboratory profiles    |                          |                          |         |
| Bilirubin (mmol/l)               | 11 (8, 16)               | 10 (7, 10)               | 0.22    |
| Creatinine (mmol/l)              | 72 (57, 101)             | 75 (60, 107)             | 0.31    |
| C-Reactive Protein (mg/l)        | 154 (102, 209)           | 133 (60, 204)            | 0.31    |
| Lymphocytes $10^9$/l             | 0.8 (0.6, 1.3)           | 0.8 (0.5, 1.3)           | 0.31    |
| Neutrophil/lymphocyte ratio      | 6.7 (5, 12.2)            | 10.0 (7.7, 19.5)         | 0.006*  |
| White cell counts $10^9$/l       | 8.1 (5.6, 11.7)          | 10.7 (7.1, 16.0)         | 0.004*  |
| ICU organ support                |                          |                          |         |
| Cardiovascular support, n (%)    | 30 (32.2%)               | 16 (30.2%)               | 0.85    |
| Non-invasive ventilation alone, n (%) | 35 (37.6%)              | 30 (56.6%)               | 0.04*   |
| Mechanical ventilation, n (%)    | 54 (58.1%)               | 14 (26.4%)               | < 0.001* |
| Renal replacement therapy, n (%) | 19 (20.4%)               | 5 (9.4%)                 | 0.11    |

Charlson comorbidity index was higher in patients with non-COVID-19 viral pneumonia group with a proportional variation in individual comorbidities between both groups. There was an increased prevalence of respiratory comorbidities, particularly airways disease with asthma and chronic obstructive pulmonary disease among group 2, whereas diabetes mellitus was more frequent in COVID-19 pneumonia. The ICU admission severity indices (APACHE II and SOFA) were similar between groups with a slightly lower worse admission oxygenation defined by PaO$_2$/FiO$_2$ ratio in the COVID-19 group which was not statistically significant. The estimated in-hospital mortality from the calculated APACHE II scores at presentation for both groups was around 15%. The baseline routine laboratory variables such as bilirubin, creatinine, CRP, lymphocytes and white cell counts did not show any difference between both groups. However, the neutrophil to lymphocyte ratio was higher in patients with non-COVID pneumonia (Table 1).

Among the patients with non-COVID-19 viral pneumonia (group 2), the viral pathogens identified were influenza A (26.4%), rhinovirus (26.4%), RSV (15.1%), metapneumovirus (13.2%), parainfluenza T3 (11.3%) and adenovirus (7.8%) (Table 2). As expected, there was an increased seasonal prevalence of influenza and RSV viruses during winter months and rhinovirus did not show seasonal variation. (Fig. 1). Co-bacterial infection defined as positive bacterial microbiology during the first 48 hours of ICU
admission was 16.4% and 11.3% respectively. Moreover, there were differences in the type of bacterial infection between both groups (Table 3).

| Type of Virus                  | Number (%) (N = 53) |
|-------------------------------|---------------------|
| Influenza A                   | 14 (26.4%)          |
| Rhinovirus                    | 14 (26.4%)          |
| Respiratory syncytial virus   | 8 (15.1%)           |
| Metapneumovirus               | 7 (13.2%)           |
| Parainfluenza T3              | 6 (11.3%)           |
| Adenovirus                    | 4 (7.5%)            |

Table 3
Co-infections identified during ICU admission. Co-infection defined as significant pathogen identified in 48 hours prior to or after admission to critical care.

| Pathogen                        | Viral Pneumonia N = 53 | COVID-19 Pneumonia N = 93 |
|---------------------------------|------------------------|---------------------------|
| Staphylococcus Aureus           | 1                      | 3                         |
| Streptococcus pneumoniae        | 2                      | -                         |
| Pneumococcus                    | 2                      | -                         |
| Pseudomonas Aeruginosa          | 1                      | -                         |
| Klebsiella                      | -                      | 1                         |
| Proteus Mirabilis               | -                      | 1                         |
| E. coli                         | -                      | 1                         |

Proportion of Patients with significant co-infection identified: 11.3% vs 6.4%

Although there was no difference in the need for cardiovascular support between groups, invasive mechanical ventilation was more common in COVID-19 pneumonia (58% group 1 vs 26% group 2). Whereas more patients in group 2 had NIV alone to manage their respiratory failure. The incidence of renal replacement therapy was also much higher in COVID-19 patients (20% group 1 vs 9% group 2). There were no differences in 28-day, ICU or hospital mortality between two groups (Table 4, Fig. 2). The
overall hospital mortality was 18% and 22.6% for groups 1 and 2 respectively. However, the median length of ICU and hospital stay was much more prolonged for COVID-19 patients.

Table 4
Outcome of all patients. Data are presented as median (Interquartile Range) or numbers (percentage) unless otherwise stated. *P < 0.05 as assessed by Fisher’s Exact test for categorical variables and Mann-Whitney U test for continuous variables.

| Outcomes                     | Group 1                                      | Group 2                                      | p-value |
|------------------------------|----------------------------------------------|----------------------------------------------|---------|
|                              | COVID 19 pneumonia (N = 93)                  | Other Viral pneumonia (N = 53)               |         |
| Length of ICU stay (days)    | 8 (3, 22)                                    | 4 (2, 7)                                    | < 0.001*|
| Length of hospital stay (days)| 22 (10, 36)                                  | 11 (7, 24)                                  | < 0.001*|
| 28-day mortality, n (%)      | 15 (16.1%)                                   | 8 (15.1%)                                   | 0.99    |
| ICU mortality, n (%)         | 16 (17.2%)                                   | 11 (20.7%)                                  | 0.66    |
| Hospital mortality, n (%)    | 16 (17.2%)                                   | 12 (22.6%)                                  | 0.51    |

Discussion

This study compared the differences in demographics, organ support measures and clinical outcomes during ICU admissions of severe COVID-19 pneumonia with historic patients admitted with other viral pneumonia from the previous year. The COVID-19 group was less frail as defined by the clinical frailty score (CFS) and had quantitatively lower overall Charlson's Comorbidity Index score. Although the COVID-19 ICU patients were younger by a median age of 8 years (median age of 58 vs 65), this was not statistically significant. Moreover, there was a trend towards increased male predominance (60% vs 45%) in the COVID-19 group. Obesity (defined by a body mass index of > 30) and diabetes mellitus was more prevalent in COVID-19 pneumonia. Likewise, none-white ethnicity is proportionally higher in COVID-19 pneumonia (41% vs 6%). Airways diseases with asthma and COPD were more common in non-COVID-19 viral pneumonia. Similar to other published cohort studies, influenza A and rhinovirus were the most common causes of severe respiratory failure leading to ICU admission accounting for > 50% of viral pneumonia in our population [4, 8, 9]. The seasonality of severe viral infection was as anticipated, where influenza and RSV were more prevalent in winter months. Rhinovirus was present throughout the year [4].

Despite the similarities in the ICU severity indices such as APACHE II, SOFA and oxygenation index defined as PaO2/FiO2 (mmHg) ratios between groups, there were variations in ICU organ support measures provided. More patients with COVID-19 needed invasive mechanical ventilation and a trend towards increased renal replacement therapy requirement, which was not significant. The onset of symptoms to hospitalisation is prolonged in COVID-19 patients. This is consistent with already established timelines of COVID-19 reaching peak severity at 7–10 days and suggests that other viral pneumonia has a more acute onset of peak severity [10]. Moreover, COVID-19 patients also had a higher median number of total
hospital days, consistent with a study from Finland showing longer hospitalization in COVID-19 patients compared to those with influenza [11]. Regardless of these differences, the ICU, hospital and 28-day mortality was similar between both groups. Our finding of similar mortality is consistent with a large multicentre study comparing critically ill COVID-19 with H1N1 influenza pandemic during 2009 [12]. Our overall mortality is lower than previously published national and international data sets [2, 13]. In contrast, an American study comparing critically ill hospitalised patients with influenza and COVID-19 showed a mortality of 40% in COVID-19 group with a significantly lower mortality among the influenza group [14]. However, our critically ill cohort was inclusive of all respiratory viruses and the variations in mortality could be accounted for by local practice and management guidelines, as our study only consisted of analysis of single centre data.

Similar to our findings, one prospective study found those with COVID-10 were less likely to have underlying pulmonary disease [11]. Our findings are also consistent with regards to patient's characteristics including the type of co-morbidities and others have also highlighted that those hospitalised or critically ill COVID-19 patients are more likely to have obesity, diabetes mellitus, and kidney disease, or be of black race than those with influenza [12, 14]. Moreover, those hospitalised with COVID-19 appears to have increased tendency to develop acute respiratory distress syndrome, pulmonary embolism, septic shock and haemorrhagic stroke than those with Inuenza but less frequently develop atrial fibrillation or myocardial infarction [15].

Despite the similar ICU admission scores and the degree of hypoxia at presentation, there was an increased need for mechanical ventilation in the COVID-19 group with associated prolonged duration of hospitalisation. Although, renal replacement therapy was also more common in COVID-19 patients, this was not statistically significant. This is consistent with previously published data that a higher proportion of patients with COVID-19 required intensive care and mechanical ventilation than those with influenza, with an increased risk of developing extra pulmonary organ dysfunction [11, 15, 16]. In contrast, an Australian study comparing COVID-19 patients with H1N1 influenza pandemic in 2009, concluded that fewer proportions of COVID-19 admissions needed invasive mechanical ventilation [12]. This is likely due to the reflection of variations in pandemic severity and utilisation of ICU healthcare between countries. Although most admission laboratory variables were similar between groups, the neutrophil/lymphocyte ratio (NLR) was significantly lower in the COVID-19 group. This finding of high NLR in the non-COVID-19 group may imply increased neutrophilic response possibly due to associated bacterial co-infections in this group.

Our study has several limitations. This was a single centre retrospective cohort study with a small group of patients. Larger samples are needed for further confirmation of study findings. Data from both groups were taken during different time periods - this is attributed to a significant lack in other respiratory viruses presenting to hospital following social distancing, and guidance from Public Health England not to test for other respiratory viruses during the first peak to save reagents for COVID-19 testing. Moreover, we only started performing an extended blood panel analysis including variables such as D-Dimer, lactate dehydrogenase, ferritin and high-sensitive cardiac troponin during the COVID-19 pandemic and as a
result, these were not done routinely or consistently in viral pneumonia patients. Therefore, we were unable to directly compare these extended panels between both groups.

**Conclusion**

To our knowledge, this is the first cohort study from the UK comparing ICU admissions of severe non-covid-19 viral pneumonia with COVID-19 pneumonia. We have identified key differences in patient specific variables such as onset of symptoms prior to hospitalisation, BMI, frailty score and the type of comorbidities. Proportionately more patients with COVID-19 patients had obesity, diabetes mellitus, and had lesser chronic respiratory comorbidities. The COVID-19 patients also had lower neutrophil to lymphocyte ratio. Despite these differences, the ICU specific scores were similar and there was no difference in mortality between groups. The COVID-19 patients had prolonged ICU stay and overall hospitalisations. In comparison with previously published data from international studies, our findings are consistent, except the key difference of lower ICU and hospital mortality in our population.

**Acknowledgment**

We thank Stephen Aplin surveillance officer in the Infection prevention team at university hospital Southampton for his support in getting some of the data for this work

**Declarations**

**Acknowledgment**

We thank Stephen Aplin surveillance officer in the Infection prevention team at university hospital Southampton for his support in getting some of the data for this work

**Declarations**

1. **Funding:** This work was performed in authors own time, no additional funding was obtained for the work.
2. **Conflicts of interest:** Nothing to declare or disclose
3. **Availability of Data and material:** available on request
4. **Code of availability:** not applicable
5. **Ethics approval:** The study was approved by local ethics committee for retrospective data collection (RHM CRI 0370/ IRAS 232922) and due to the nature of the study patient consent was waived.
6. **Contributions:**

AD and SK conceived and designed the study and contributed to data collection, data analysis and manuscript writing and editing. KD and RS contributed to data collection and manuscript writing and editing. SP contributed to data collection and manuscript editing.
g. Consent to participate (as per point e: this was waived)

h. Consent for publication (as per point e: this was waived)

References

1. Source: The Intensive Care Society. https://www.ics.ac.uk/ICS/Pdfs/COVID-19/Recovery_and_Restitution_of_ICU. Accessed on 28/05/2021.

2. These data arise from the ICNARC Case Mix Programme Database. The Case Mix Programme is the national clinical audit of patient outcomes from adult critical care coordinated by the Intensive Care National Audit & Research Centre (ICNARC). For more information for the representativeness and quality of these data, please contact ICNARC. Date of access 28/05/2021. https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports

3. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C, Horby PW, Nguyen-Van-Tam JS, Ho A, Russell CD, Dunning J, Openshaw PJ, Baillie JK, Semple MG; ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020 May 22;369:m1985. doi: 10.1136/bmj.m1985.

4. Choi SH, Hong SB, Ko GB, Lee Y, Park HJ, Park SY, Moon SM, Cho OH, Park KH, Chong YP, Kim SH, Huh JW, Sung H, Do KH, Lee SO, Kim MN, Jeong JY, Lim CM, Kim YS, Woo JH, Koh Y. Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med. 2012;186(4):325-32.

5. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–1499.

6. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
7. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Mushler DM, Restrepo MI, Whitney CG. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67.

8. Wiemken T, Peyrani P, Bryant K, Kelley RR, Summersgill J, Arnold F, Carrico R, McKinney WP, Jonsson C, Carrico K, Ramirez J. Incidence of respiratory viruses in patients with community-acquired pneumonia admitted to the intensive care unit: results from the Severe Influenza Pneumonia Surveillance (SIPS) project. Eur J Clin Microbiol Infect Dis. 2013 May;32(5):705-10.

9. Loubet P, Voiriot G, Houhou-Fidouh N, Neuville M, Bouadma L, Lescure FX, Descamps D, Timsit JF, Yazdanpanah Y, Visseaux B. Impact of respiratory viruses in hospital-acquired pneumonia in the intensive care unit: A single-center retrospective study. J Clin Virol. 2017;91:52-57.

10. COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2021;47(1):60-73.

11. Auvinen R, Nohynek H, Syrjänen R, Ollgren J, Kerttula T, Mäntylä J, Ikonen N, Loginov R, Haveri A, Kurkela S, Skogberg K. Comparison of the clinical characteristics and outcomes of hospitalized adult COVID-19 and influenza patients - a prospective observational study. Infect Dis (Lond). 2021;53(2):111-121.

12. Serpa Neto A, Burrell AJ, Bailey M, Broadley T, Cooper DJ, French CJ, Pilcher D, Plummer MP, Trapani T, Webb SA, Bellomo R, Udy A; SPRINT-SARI Australia and ANZIC Influenza Investigators. Comparison of Critical Care Occupancy and Outcomes of Critically ill Patients during the 2020 COVID-19 Winter Surge and 2009 H1N1 Influenza Pandemic in Australia. Ann Am Thorac Soc. 2020 Dec 23. doi: 10.1513/AnnalsATS.202010-1311OC. Epub ahead of print.
13. Armstrong RA, Kane AD, Kursumovic E, Oglesby FC, Cook TM. Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies. Anaesthesia. 2021 Apr;76(4):537-548. doi: 10.1111/anae.15425. Epub 2021 Feb 1.

14. Cobb NL, Sathe NA, Duan KI, Seitz KP, Thau MR, Sung CC, Morrell ED, Mikacenic C, Kim HN, Liles WC, Luks AM, Town J, Pipavath S, Wurfel MM, Hough CL, West TE, Bhatraju PK. Comparison of Clinical Features and Outcomes in Critically Ill Patients Hospitalized with COVID-19 versus Influenza. Ann Am Thorac Soc. 2021;18(4):632-640.

15. Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, Quantin C. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021;9(3):251-259.

16. Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, Ma Z, Huang Y, Liu W, Yao Y, Zeng R, Xu G. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. J Am Soc Nephrol. 2020 Jun;31(6):1157-1165.

Tables
| Variables                          | Group 1 COVID 19 pneumonia (N= 93) | Group 2 Other Viral pneumonia (N=53) | p-value |
|-----------------------------------|------------------------------------|--------------------------------------|---------|
| Age                               | 58 (47, 66)                        | 65 (50, 71)                          | 0.13    |
| Male (%)                          | 60%                                | 45%                                  | 0.09    |
| Symptomatic days prior to admission| 7 (5, 10)                          | 4 (3, 7)                             | <0.001* |
| BMI >30 kg/m², n (%)              | 39 (41.9%)                         | 12 (22.6%)                           | 0.02*   |
| Clinical Frailty Scale (CFS)      | 2 (1, 3)                           | 3 (3, 5)                             | <0.001* |
| Charlson’s comorbidity index (CCI)| 2 (1, 3)                           | 3 (1.5, 5)                           | 0.02*   |
| Race/ethnic group                 |                                    |                                      | <0.001* |
| White, n (%)                      | 55 (59%)                           | 50 (94%)                             |         |
| Other, n (%)                      | 38 (41%)                           | 3 (6%)                               |         |
| **Comorbidities, n (%)**          |                                    |                                      |         |
| COPD/Asthma                       | 15 (16.1%)                         | 18 (34.0%)                           | 0.02*   |
| Other respiratory disease         | 7 (7.5%)                           | 7 (13.2%)                            | 0.38    |
| Chronic kidney disease            | 7 (7.5%)                           | 7 (13.2%)                            | 0.38    |
| Congestive cardiac failure        | 4 (4.3%)                           | 3 (5.7%)                             | 0.70    |
| Diabetes mellitus                 | 28 (30.0%)                         | 7 (13.2%)                            | 0.03*   |
| Hypertension                      | 38 (40.9%)                         | 14 (26.4%)                           | 0.11    |
| Ischemic heart disease            | 8 (8.6%)                           | 5 (9.4%)                             | 0.99    |
| Immunosuppression                 | 13 (14.0%)                         | 13 (24.5%)                           | 0.12    |
| **ICU severity indices**          |                                    |                                      |         |
| APACHE II Score                   | 14 (11, 23)                        | 14 (9.5, 19)                         | 0.18    |
| SOFA Score                        | 4 (3, 6)                           | 3 (2, 6)                             | 0.09    |
| PaO₂/FiO₂ ratio (mmHg)            | 114.8 (99.0, 137.3)                | 126.8 (95.3, 203.3)                  | 0.11    |
| **Admission laboratory profiles** |                                    |                                      |         |
| Bilirubin (mmol/l)                | 11 (8, 16)                         | 10 (7, 10)                           | 0.22    |
| Creatinine (mmol/l)               | 72 (57, 101)                       | 75 (60, 107)                         | 0.31    |
| C-Reactive Protein (mg/l)         | 154 (102, 209)                     | 133 (60, 204)                        | 0.31    |
|                        | Group 1 (N=50)   | Group 2 (N=53)   | P value |
|------------------------|------------------|------------------|---------|
| **Lymphocytes 10⁹/l**  | 0.8 (0.6, 1.3)   | 0.8 (0.5, 1.3)   | 0.31    |
| **Neutrophil/lymphocyte ratio** | 6.7 (5, 12.2) | 10.0 (7.7, 19.5) | 0.006*  |
| **White cell counts 10⁹/l** | 8.1 (5.6, 11.7) | 10.7 (7.1, 16.0) | 0.004*  |

**ICU organ support**

|                        | Group 1 (N=50)   | Group 2 (N=53)   | P value |
|------------------------|------------------|------------------|---------|
| Cardiovascular support, n (%) | 30 (32.2%) | 16 (30.2%) | 0.85   |
| Non-invasive ventilation alone, n (%) | 35 (37.6%) | 30 (56.6%) | 0.04*  |
| Mechanical ventilation, n (%) | 54 (58.1%) | 14 (26.4%) | <0.001*|
| Renal replacement therapy, n (%) | 19 (20.4%) | 5 (9.4%) | 0.11   |

**Table 1.** Patient demographics on admission, disease severity indices, intensive care interventions and admission laboratory markers from all COVID-19 admitted patients. Data are presented as median (Interquartile Range) or numbers (percentage) unless otherwise stated. *P<0.05 as assessed by Fisher’s Exact test for categorical variables and Mann-Whitney U test for continuous variables. APACHE II, Acute Physiology and Chronic Health Evaluation II score; BMI, Body Mass Index; PaO₂/FiO₂, ratio of arterial oxygen partial pressure to fractional inspired oxygen; SOFA, Sequential Organ Failure Assessment score.

| Type of Virus               | Number (%) |
|-----------------------------|------------|
| N=53                        |            |
| Influenza A                 | 14 (26.4%) |
| Rhinovirus                  | 14 (26.4%) |
| Respiratory syncytial virus | 8 (15.1%)  |
| Metapneumovirus             | 7 (13.2%)  |
| Parainfluenza T3            | 6 (11.3%)  |
| Adenovirus                  | 4 (7.5%)   |

**Table 2.** Viral pathogens identified in group 2 and the seasonality of their infections.
## Table 3

| Pathogen                        | Viral Pneumonia | COVID-19 Pneumonia |
|---------------------------------|-----------------|--------------------|
| Staphylococcus Aureus           | 1               | 3                  |
| Streptococcus pneumoniae        | 2               | -                  |
| Pneumococcus                    | 2               | -                  |
| Pseudomonas Aeruginosa          | 1               | -                  |
| Klebsiella                      | -               | 1                  |
| Proteus Mirabilis               | -               | 1                  |
| E. coli                         | -               | 1                  |

Proportion of Patients with significant co-infection identified: 11.3% vs. 6.4%

Table 3: Co-infections identified during ICU admission. Co-infection defined as significant pathogen identified in 48 hours prior to or after admission to critical care.

### Outcomes

| Outcomes                        | Group 1                     | Group 2                     | p-value  |
|---------------------------------|-----------------------------|-----------------------------|----------|
| COVID 19 pneumonia (N= 93)      | 8 (3, 22)                   | 4 (2, 7)                    | <0.001*  |
| Other Viral pneumonia (N=53)    | 22 (10, 36)                 | 11 (7, 24)                  | <0.001*  |
| 28-day mortality, n (%)         | 15 (16.1%)                  | 8 (15.1%)                   | 0.99     |
| ICU mortality, n (%)            | 16 (17.2%)                  | 11 (20.7%)                  | 0.66     |
| Hospital mortality, n (%)       | 16 (17.2%)                  | 12 (22.6%)                  | 0.51     |
Table 4. Outcome of all patients. Data are presented as median (Interquartile Range) or numbers (percentage) unless otherwise stated. *P<0.05 as assessed by Fisher's Exact test for categorical variables and Mann-Whitney U test for continuous variables.

Figures

Figure 1

Seasonal variations of severe viral pneumonia ICU admissions for the year between January-December 2019.
Figure 2

Survival probability at day-28 between critically ill ICU COVID-19 pneumonia and other viral pneumonia patients.